JERUSALEM PHARMACEUTICALS CO. LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.63 USD | 0.00% |
|
+0.28% | -4.47% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 58.32 | 50.4 | 49.86 | 50.94 | 59.04 | 68.4 |
| Enterprise Value (EV) 1 | 57.5 | 53.52 | 51.69 | 48.08 | 53.44 | 62.11 |
| P/E ratio | 9.52 x | 9.42 x | 13.4 x | 7.72 x | 8.23 x | 9.83 x |
| Yield | 3.09% | 3.57% | 2.89% | 4.24% | 4.57% | 2.63% |
| Capitalization / Revenue | 1.89 x | 1.48 x | 1.37 x | 1.1 x | 1.28 x | 1.72 x |
| EV / Revenue | 1.87 x | 1.57 x | 1.42 x | 1.04 x | 1.16 x | 1.57 x |
| EV / EBITDA | 7.93 x | 7.79 x | 8.69 x | 4.83 x | 5.07 x | 6.11 x |
| EV / FCF | 150 x | -24 x | -43.7 x | 19.4 x | 4.25 x | 12.2 x |
| FCF Yield | 0.67% | -4.17% | -2.29% | 5.16% | 23.5% | 8.18% |
| Price to Book | 1.2 x | 0.96 x | 0.84 x | 0.77 x | 0.92 x | 1.01 x |
| Nbr of stocks (in thousands) | 18,000 | 18,000 | 18,000 | 18,000 | 18,000 | 18,000 |
| Reference price 2 | 3.240 | 2.800 | 2.770 | 2.830 | 3.280 | 3.800 |
| Announcement Date | 4/1/19 | 5/7/20 | 5/10/21 | 3/31/22 | 4/1/23 | 4/30/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 30.8 | 34.09 | 36.4 | 46.23 | 46.14 | 39.65 |
| EBITDA 1 | 7.246 | 6.873 | 5.946 | 9.946 | 10.53 | 10.17 |
| EBIT 1 | 5.664 | 5.194 | 4.012 | 7.985 | 8.808 | 8.982 |
| Operating Margin | 18.39% | 15.24% | 11.02% | 17.27% | 19.09% | 22.65% |
| Earnings before Tax (EBT) 1 | 6.115 | 5.027 | 3.741 | 7.622 | 9.03 | 8.821 |
| Net income 1 | 6.125 | 5.351 | 3.725 | 6.598 | 7.174 | 6.957 |
| Net margin | 19.88% | 15.7% | 10.23% | 14.27% | 15.55% | 17.54% |
| EPS 2 | 0.3403 | 0.2973 | 0.2070 | 0.3665 | 0.3985 | 0.3865 |
| Free Cash Flow 1 | 0.3841 | -2.233 | -1.182 | 2.482 | 12.57 | 5.082 |
| FCF margin | 1.25% | -6.55% | -3.25% | 5.37% | 27.25% | 12.82% |
| FCF Conversion (EBITDA) | 5.3% | - | - | 24.95% | 119.34% | 49.97% |
| FCF Conversion (Net income) | 6.27% | - | - | 37.62% | 175.25% | 73.05% |
| Dividend per Share 2 | 0.1000 | 0.1000 | 0.0800 | 0.1200 | 0.1500 | 0.1000 |
| Announcement Date | 4/1/19 | 5/7/20 | 5/10/21 | 3/31/22 | 4/1/23 | 4/30/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 3.12 | 1.83 | - | - | - |
| Net Cash position 1 | 0.82 | - | - | 2.86 | 5.6 | 6.29 |
| Leverage (Debt/EBITDA) | - | 0.4541 x | 0.307 x | - | - | - |
| Free Cash Flow 1 | 0.38 | -2.23 | -1.18 | 2.48 | 12.6 | 5.08 |
| ROE (net income / shareholders' equity) | 11.9% | 9.66% | 6.3% | 9.55% | 10.8% | 10.5% |
| ROA (Net income/ Total Assets) | 5.67% | 4.94% | 3.38% | 6.06% | 6.45% | 6.6% |
| Assets 1 | 108 | 108.3 | 110.3 | 108.8 | 111.2 | 105.4 |
| Book Value Per Share 2 | 2.700 | 2.900 | 3.300 | 3.690 | 3.570 | 3.770 |
| Cash Flow per Share 2 | 0.1400 | 0.0600 | 0.1100 | 0.3000 | 0.4300 | 0.3700 |
| Capex 1 | 1.39 | 1.57 | 1.46 | 2.19 | 0.68 | 1.36 |
| Capex / Sales | 4.51% | 4.6% | 4.01% | 4.74% | 1.48% | 3.42% |
| Announcement Date | 4/1/19 | 5/7/20 | 5/10/21 | 3/31/22 | 4/1/23 | 4/30/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.47% | 65.34M | |
| +23.58% | 45.07B | |
| +30.84% | 23.39B | |
| +25.20% | 16.08B | |
| +19.32% | 14.6B | |
| +67.99% | 14.01B | |
| -0.05% | 6.79B | |
| -13.00% | 6.38B | |
| -8.87% | 5.73B | |
| +13.53% | 5.64B |
- Stock Market
- Equities
- JPH Stock
- Financials Jerusalem Pharmaceuticals Co. Ltd.
